Gilead Sciences, Teva and Bristol Myers Squibb sued
The lawsuit launched by major US pharmacy chains CVS and Rite Aid against Gilead Sciences, Teva and Bristol Myers Squibb specifically desires billions of dollars’ worth of reverse-payment agreements between the trio, that led to the withholding of generic versions of HIV drugs Viread, Atripla, Truvada and Evotaz from the market.

It is alleged that between 2004 to 2017, Gilead made tens of billions of dollars from HIV medications while introducing only a single new pharmaceutical compound. In addition, Gilead engaged in settlement agreements, collusive collaborations and product-hopping schemes whilst unfairly increasing the exorbitant pricing for its HIV medications, prior to generics market entry. Gilead is also accused of suppressing competition of certain drugs and of collaborating with Teva to not launch generic versions. Gilead collaborated with Bristol Myers Squibb to develop some of the HIV drugs, yet the suit argues that these were in fact created by Czech institution in the 1980s.

Illegal collaboration of Taro Pharmaceuticals USA, Novartis’ Sandoz and Apotex
The US$450 million to be paid by Taro Pharmaceuticals USA, Novartis’ Sandoz and Apotex is in addition to the more than US$400 million already paid by the trio in criminal penalties related to price fixing. In addition, the companies have entered a five-year corporate integrity agreement, which includes internal monitoring and price transparency provisions, among other checks and balances.

Taro will pay over US$200 million, for alleged violations involving the non-steroidal drug etodolac, and nystatin-triamcinolone cream and ointment to treat skin infections. Sandoz will pay US$185 million due to alleged issues with benazepril HCTZ, used to treat hypertension, and clobetasol, a corticosteroid used to treat skin conditions. Apotex will pay US$49 million in connection with its sale of pravastatin, a drug used to treat high cholesterol and triglyceride levels.

Related articles
FDA voices concern around drug patents and competition

FDA approval for schizophrenia and HIV generics from Zydus Cadila and Lupin

Teva launches first Truvada and Atripla generics and two digital inhalers

Sun Pharma ends attempt to gain full control of Taro

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.